Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, open-label study to determine the safety and efficacy of single-agent CC-5013 [lenalidomide] in subjects with relapsed or refractory multiple myeloma.

Next Previous
X
Search
Trial Profile

A multicenter, open-label study to determine the safety and efficacy of single-agent CC-5013 [lenalidomide] in subjects with relapsed or refractory multiple myeloma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use

    • Most Recent Events

    • 29 Sep 2009 Actual end date changed from Dec 2005 to Mar 2007 as reported by ClinicalTrials.gov.
    • 08 Jun 2009 An analysis of this trial is to be presented at the 14th Congress of the European Hematology Association (EHA), according to a Celgene media release.
    • 06 Jun 2008 Status changed to completed as reported in an abstract presented at ASCO 2008.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top